Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $18.20.

BWAY has been the topic of a number of recent research reports. New Street Research reissued a “buy” rating on shares of Brainsway in a report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Brainsway in a research note on Friday. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Zacks Research cut Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings downgraded Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 29th.

Brainsway Price Performance

BWAY stock opened at $11.15 on Wednesday. The firm has a market cap of $448.79 million, a price-to-earnings ratio of 25.20 and a beta of 1.36. Brainsway has a 1-year low of $7.14 and a 1-year high of $17.40. The firm has a fifty day moving average price of $12.82 and a two-hundred day moving average price of $13.93.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The company had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.54 million. As a group, analysts expect that Brainsway will post 0.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Brainsway during the first quarter valued at $40,000. Ballast Advisors LLC bought a new position in shares of Brainsway during the first quarter worth about $55,000. Royal Bank of Canada increased its holdings in shares of Brainsway by 84.2% in the 1st quarter. Royal Bank of Canada now owns 15,490 shares of the company’s stock worth $206,000 after acquiring an additional 7,080 shares during the period. Calamos Advisors LLC acquired a new stake in shares of Brainsway in the 3rd quarter worth about $135,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Brainsway by 434.6% in the 2nd quarter. NewEdge Advisors LLC now owns 18,830 shares of the company’s stock worth $292,000 after acquiring an additional 15,308 shares during the period. 30.11% of the stock is currently owned by institutional investors.

About Brainsway

BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.